TrialAmerican journal of hematology2026

RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma.

Cong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.